Evidence map›Paper›PMID 28588704›Full record

ArticleOncology letters2017

Ell3 stimulates 5-FU resistance in a breast cancer cell line.

Isaac Kim, Kwang-Soo Kim, Ok-Seon Kwon, Hyuk-Jin Cha, Kyung-Soon Park

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Isaac KimDepartment of Biomedical Science, College of Life Science, CHA University, Seongnam-si, Gyeonggi-do 13496, Republic of Korea.
Kwang-Soo KimDepartment of Biomedical Science, College of Life Science, CHA University, Seongnam-si, Gyeonggi-do 13496, Republic of Korea.
Ok-Seon KwonDepartment of Life Science, College of Natural Science, Sogang University, Seoul 04107, Republic of Korea.
Hyuk-Jin ChaDepartment of Life Science, College of Natural Science, Sogang University, Seoul 04107, Republic of Korea.
Kyung-Soon ParkDepartment of Biomedical Science, College of Life Science, CHA University, Seongnam-si, Gyeonggi-do 13496, Republic of Korea.
CHA University · KRSogang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ell3 is an RNA polymerase II transcription elongation factor that acts as a negative regulator of p53 expression, and regulates cell proliferation and survival. Recent studies by our group have demonstrated that ectopic expression of Ell3 in breast cancer cell lines enhances cell proliferation, potentiates cancer stem cell properties, and promotes 5-Fluorouracil (5-FU) resistance. In the present study, the underlying mechanism for the induction of 5-FU resistance was investigated in Ell3 over-expressing MCF-7 cells (Ell3 OE cells). By comparing the gene expression profiles of Ell3 OE cells with control cells, the present data revealed that Lipocalin2 (LCN2) and Wnt signaling activity are associated with 5-FU resistance of Ell3 OE. siRNA-mediated suppression of LCN2 reversed 5-FU resistance in Ell3 OE cells. Chemical inhibition of Wnt signaling also reversed 5-FU resistance in Ell3 OE cells. Furthermore, the expression levels of survivin, which is a direct transcriptional target of Wnt/β-catenin and an inhibitor of apoptosis, were markedly elevated when Ell3 OE cells were treated with 5-FU, as detected by western blot analysis. These findings suggest that enhanced expression of LCN2 and activation of the Wnt signaling pathway may induce 5-FU resistance in Ell3 OE cells as a means of evading apoptosis.

Indexed as

5-Fluorouracil resistancebreast cancerEll3Lipocalin2WNT signaling

Identifiers

PMID28588704
PMCPMC5452875
OpenAlexW2605026686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.